Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Rises By 26.4%

Biofrontera Inc. (NASDAQ:BFRI) saw a significant increase in short interest in April. As of April 15th, there was short interest totalling 44,000 shares, an increase of 26.4% from the March 31st total of 34,800 shares. Based on an average trading volume of 759,100 shares, the short-interest ratio is currently 0.1 days. Approximately 1.2% of the company’s stock are sold short.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently bought a new stake in Biofrontera stock. Rosalind Advisors Inc. bought a new stake in shares of Biofrontera Inc. (NASDAQ:BFRI) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 504,261 shares of the company’s stock, valued at approximately $777,000. Biofrontera accounts for about 0.7% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th largest holding. Rosalind Advisors Inc. owned about 9.91% of Biofrontera at the end of the most recent reporting period. 10.08% of the stock is owned by hedge funds and other institutional investors.

Biofrontera Trading Down 5.9 %

Shares of NASDAQ:BFRI traded down $0.10 during midday trading on Friday, hitting $1.59. 50,733 shares of the company’s stock were exchanged, compared to its average volume of 124,658. The stock has a 50 day moving average price of $1.41 and a 200-day moving average price of $2.45. Biofrontera has a 12 month low of $0.61 and a 12 month high of $13.42.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings data on Friday, March 15th. The company reported ($2.33) earnings per share (EPS) for the quarter. Biofrontera had a negative return on equity of 344.98% and a negative net margin of 59.09%. The firm had revenue of $10.60 million during the quarter. As a group, equities research analysts expect that Biofrontera will post -4.01 EPS for the current fiscal year.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.